Med. praxi. 2014;11(1):26-28

Multiple Sclerosis - Myths and Realities

MUDr.Jiří Piťha
MS Centrum Teplice, Neurologické oddělení KZ a. s. &ndash, Nemocnice Teplice o. z.

Multiple sclerosis is the most common neurological disease of young people and middle-age, which can lead to permanent disability.

The disease is heterogeneous in its immunopathogenesis and clinical course. In recent years there has been a fundamental change in

the perception of the need for early diagnosis with the possibility of employing an effective treatment in the phase of the first clinical

episode. Yet still survives myths and half-truths that the practitioner can make a distorted view of current reality, consisting of active

and individualized approach to the patient with multiple sclerosis.

Keywords: multiple sclerosis, diagnosis, treatment, symptoms, general practitioner

Published: February 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Piťha J. Multiple Sclerosis - Myths and Realities. Med. praxi. 2014;11(1):26-28.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Polman CH, Reingold SC, Banwel B, et al. Diagnostic kriteria for multiple sclerosis: 2010 revisions to the McDonald kriteria. Ann Neurol 2011; 69: 292-302. Go to original source... Go to PubMed...
    2. McDonald WI, Noseworthy JH. Multiple Sclerosis 2. Philadelphia: Butterworth-Heinemann; 2003: 377.
    3. Cook SD. Handbook of Multiple Sclerosis. 3rd ed. New York: Marcel Dekker, Inc.; 2001: 687. Go to original source...
    4. Murray TJ. Multiple Sclerosis: The History of a Disease. New York: Demos Med Publishing; 2005: 580.
    5. Repovic P, Lublin FD. Treatment of multiple sclerosis exacerbations. Neurol Clin. 2011; 29: 389-400. Go to original source... Go to PubMed...
    6. Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372: 1502-1517. Go to original source... Go to PubMed...
    7. Richert ND, Ostuni JL, Bash CN, et al. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler. 2001; 7(1): 49-58. Go to original source... Go to PubMed...
    8. Vattakatuchery JJ, Rickards H, Cavanna AE. Pathogenic mechanisms of depression in multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2011; 23(3): 261-276. Go to original source... Go to PubMed...
    9. Sadovnick AD, Eisen K, Ebers GC, et al. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41: 1193-1196. Go to original source... Go to PubMed...
    10. Jongen PJ, Ter Horst AT, Brands AM. Cognitive impairment in multiple sclerosis. Minerva Med. 2012; 103(2): 73-96. Go to PubMed...
    11. Mowry EM. Natural history of multiple sclerosis: early prognostic factors. Neurol Clin. 2011; 29(2): 279-292. Go to original source... Go to PubMed...
    12. Tintoré M. Rationale for early intervention with immunomodulatory treatments. J Neurol. 2008; 255(Suppl 1): 37-43. Go to original source... Go to PubMed...
    13. Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J Neurol Sci. 2009; 277(Suppl 1): S42-45. Go to original source... Go to PubMed...
    14. Piťha J, Prymula R. Jaká rizika přináší očkování u pacientů s roztroušenou sklerózou? Neurol. praxi, 2013; 14(4): 188-192.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.